Adorbis2.5 mg

Adorbis is a cardioselective (beta-1 selective) beta-adrenergic blocking agent with the following indications:

Established/Approved Uses

• Hypertension: Indicated alone or in combination with other antihypertensive agents for management of high blood pressure.

Guideline-Supported Uses

• Chronic stable angina pectoris: Used to reduce the frequency of anginal attacks and improve exercise tolerance in patients with chronic stable angina.
• Chronic heart failure with reduced ejection fraction (HFrEF): Used as part of guideline-directed medical therapy (in combination with other heart failure medications such as ACE inhibitors/ARBs/ARNI, diuretics, and mineralocorticoid receptor antagonists), initiated at a very low dose and gradually up-titrated under specialist supervision, only once the patient is hemodynamically stable.

Note: Adorbis should always be used as prescribed by a physician; the indication, dose, and monitoring plan depend on the individual patient's cardiac status.

Each tablet contains Bisoprolol Hemifumarate as the active pharmaceutical ingredient. Bisoprolol Hemifumarate is available in various strengths (commonly 2.5 mg, 5 mg, and 10 mg tablets) along with standard pharmaceutical excipients.

Adorbis is a highly selective beta-1 adrenergic receptor blocking agent (a "cardioselective" beta-blocker) belonging to the beta-blocker class of cardiovascular medicines. At the doses used clinically, Adorbis preferentially blocks beta-1 receptors, which are predominantly located in cardiac tissue, resulting in reduced heart rate, reduced myocardial contractility, and reduced blood pressure, with relatively less effect on beta-2 receptors found in bronchial and vascular smooth muscle compared to non-selective beta-blockers. It is widely used in the long-term management of hypertension, chronic stable angina, and as part of evidence-based combination therapy for chronic heart failure with reduced ejection fraction.

Adorbis belongs to the therapeutic class of cardioselective (beta-1 selective) beta-adrenergic blocking agents, a subclass of the broader beta-blocker (beta-adrenoceptor antagonist) group of cardiovascular drugs.

Bisoprolol Hemifumarate is a highly selective beta-1 adrenoceptor antagonist that lacks intrinsic sympathomimetic activity and does not have clinically significant membrane-stabilizing activity at therapeutic doses.

Mechanism

By selectively blocking beta-1 receptors in the heart, Bisoprolol Hemifumarate decreases heart rate, cardiac contractility, and cardiac output, and reduces reflex sympathetic activation, thereby lowering blood pressure and myocardial oxygen demand. It also suppresses renin release from the kidneys, contributing to its antihypertensive effect.

Pharmacokinetics

• Absorption: Almost completely absorbed after oral administration with high oral bioavailability (approximately 80%) due to minimal first-pass metabolism.
• Distribution: Low plasma protein binding (approximately 30%).
• Metabolism: Metabolized in the liver via the CYP3A4 pathway; approximately 50% is metabolized and 50% is excreted unchanged in urine.
• Elimination half-life: Approximately 9-12 hours, allowing once-daily dosing.

Adorbis tablets should be taken orally, once daily, at approximately the same time each day, with or without food. Tablets should be swallowed whole with water and should not be crushed or chewed unless the tablet is scored and the physician/pharmacist has advised splitting.

Adorbis has the following clinically significant drug interactions:

• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem): Concomitant use may cause additive negative effects on heart rate, AV conduction, and contractility, increasing the risk of severe bradycardia or heart block; combination should be used with caution and close monitoring, generally under specialist supervision.
• Digoxin: Additive slowing of AV conduction and heart rate; requires monitoring of heart rate.
• Other antihypertensives, nitrates, and centrally acting agents (e.g., clonidine): May cause additive hypotensive effects; if clonidine is being co-administered and needs to be discontinued, Adorbis should be discontinued first, several days before clonidine, to avoid rebound hypertension.
• Insulin and oral antidiabetic agents: May mask signs and symptoms of hypoglycemia (e.g., tachycardia, tremor); blood glucose should be monitored closely.
• Class I antiarrhythmics (e.g., disopyramide): Additive negative inotropic and conduction effects; use with caution.
• Rifampin: May increase hepatic metabolism of Adorbis, potentially reducing its half-life and effect.

Side effects of Adorbis are generally dose-related and most common at the start of treatment or during dose up-titration.

Common

• Fatigue and tiredness
• Dizziness
• Headache
• Bradycardia (slow heart rate)
• Cold extremities
• Gastrointestinal disturbances (nausea, diarrhea)

Less Common/Serious

• Symptomatic hypotension
• Worsening of heart failure symptoms (particularly during dose up-titration)
• AV conduction disturbances
• Bronchospasm (more likely in patients with reactive airway disease; see Precautions and Warnings)
• Sleep disturbances, including vivid dreams or insomnia
• Depression (rare)
• Erectile dysfunction (rare)

Pregnancy: Adorbis should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Beta-blockers, including Adorbis, can cause fetal and neonatal effects such as bradycardia, hypotension, hypoglycemia, and intrauterine growth restriction. If used, the newborn should be monitored for these effects after delivery. Use in pregnancy should always be under close physician supervision.

Lactation: It is not known with certainty whether Adorbis is excreted in human breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted to weigh the benefits of breastfeeding against the potential risk to the infant.

Adorbis should be used with the following precautions:

• Abrupt discontinuation: Should be avoided. Sudden withdrawal of Adorbis can precipitate rebound hypertension, worsening angina, arrhythmia, or myocardial infarction, particularly in patients with underlying coronary artery disease. The dose should be tapered gradually over 1-2 weeks under physician guidance.
• Bradycardia and AV conduction effects: Heart rate should be monitored, particularly when Adorbis is combined with other rate-limiting drugs such as non-dihydropyridine calcium channel blockers or digoxin (see Interactions).
• Masking of hypoglycemia: In patients with diabetes mellitus, Adorbis can blunt the tachycardia and tremor that normally warn of hypoglycemia; blood glucose should be monitored closely.
• Reactive airway disease: Although beta-1 selectivity reduces the risk of bronchospasm compared to non-selective beta-blockers, this risk is not eliminated, particularly at higher doses. Adorbis should be used with caution and at the lowest effective dose in patients with asthma or chronic obstructive pulmonary disease.
• Heart failure titration: In the heart failure indication, dose increases must be very gradual and performed under specialist supervision, with monitoring for worsening heart failure symptoms (e.g., increasing dyspnea, edema, weight gain) during up-titration.
• Fatigue and dizziness: These are common, especially at treatment initiation; patients should use caution when driving or operating machinery until they know how they respond to the medicine.
• Peripheral vascular disease and Raynaud's phenomenon: May be aggravated.
• Anesthesia and major surgery: The anesthesiologist should be informed that the patient is taking Adorbis prior to any surgical procedure.

Overdose with Adorbis may cause severe bradycardia, hypotension, bronchospasm, acute cardiac failure, and hypoglycemia. If an overdose of Adorbis is suspected, seek immediate medical attention or contact emergency services/poison control right away. Do not attempt to manage an overdose at home. Treatment will require close monitoring and supportive care in a hospital setting.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Dose adjustment of Adorbis may be required in patients with severe renal impairment; the maximum recommended dose is generally 10 mg once daily (see Dosage and Administration).

Hepatic Impairment

Dose adjustment may be required in patients with severe hepatic impairment; use with caution and start at a lower dose.

Elderly

No overall differences in safety or effectiveness have been observed between elderly and younger patients, but elderly patients may be more sensitive to the heart-rate-lowering and blood-pressure-lowering effects; dose titration should proceed cautiously.

Pediatric Use

Safety and efficacy of Adorbis in pediatric patients have not been established. Use in children is not recommended outside of specialist supervision.

Adorbis is typically used long-term (chronic therapy) for hypertension, angina, and heart failure, as directed by the treating physician. It should not be stopped abruptly without medical advice, even if the patient feels well, as blood pressure and heart rate control require continued treatment.

Cardioselective (beta-1 selective) beta-adrenergic blocking agent (beta-blocker).

Bisoprolol Hemifumarate selectively blocks beta-1 adrenergic receptors, which are predominantly located in cardiac muscle, reducing the effects of circulating catecholamines on the heart. This results in decreased heart rate, decreased myocardial contractility, decreased cardiac output, and decreased renin release, collectively lowering blood pressure and myocardial oxygen demand.

Category C

Safety and efficacy of Adorbis have not been established in pediatric patients. Its use in children and adolescents is not routinely recommended and should only be considered by a pediatric specialist when no suitable alternative exists.